|
FR2711670B1
(fr)
|
1993-10-22 |
1996-01-12 |
Pasteur Institut |
Vecteur nucléotidique, composition le contenant et vaccin pour l'immunisation à l'encontre d'une hépatite.
|
|
US6727230B1
(en)
*
|
1994-03-25 |
2004-04-27 |
Coley Pharmaceutical Group, Inc. |
Immune stimulation by phosphorothioate oligonucleotide analogs
|
|
US6207646B1
(en)
|
1994-07-15 |
2001-03-27 |
University Of Iowa Research Foundation |
Immunostimulatory nucleic acid molecules
|
|
US7034007B1
(en)
|
1995-06-07 |
2006-04-25 |
East Carolina University |
Low adenosine anti-sense oligonucleotide, compositions, kit & method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) & surfactant depletion
|
|
US6825174B2
(en)
|
1995-06-07 |
2004-11-30 |
East Carolina University |
Composition, formulations & method for prevention & treatment of diseases and conditions associated with bronchoconstriction, allergy(ies) & inflammation
|
|
US6458366B1
(en)
|
1995-09-01 |
2002-10-01 |
Corixa Corporation |
Compounds and methods for diagnosis of tuberculosis
|
|
US6290969B1
(en)
*
|
1995-09-01 |
2001-09-18 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
|
US6592877B1
(en)
*
|
1995-09-01 |
2003-07-15 |
Corixa Corporation |
Compounds and methods for immunotherapy and diagnosis of tuberculosis
|
|
US20020147143A1
(en)
|
1998-03-18 |
2002-10-10 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
|
US6238921B1
(en)
*
|
1998-03-26 |
2001-05-29 |
Isis Pharmaceuticals, Inc. |
Antisense oligonucleotide modulation of human mdm2 expression
|
|
WO1999058118A2
(en)
*
|
1998-05-14 |
1999-11-18 |
Cpg Immunopharmaceuticals Gmbh |
METHODS FOR REGULATING HEMATOPOIESIS USING CpG-OLIGONUCLEOTIDES
|
|
CA2333901A1
(en)
*
|
1998-08-03 |
2000-02-24 |
East Carolina University |
Low adenosine anti-sense oligonucleotide agent, composition, kit and treatments
|
|
ES2394458T3
(es)
*
|
1998-09-09 |
2013-01-31 |
Genzyme Corporation |
Metilación de vectores plasmídicos
|
|
US20030235557A1
(en)
|
1998-09-30 |
2003-12-25 |
Corixa Corporation |
Compositions and methods for WT1 specific immunotherapy
|
|
US6172216B1
(en)
*
|
1998-10-07 |
2001-01-09 |
Isis Pharmaceuticals Inc. |
Antisense modulation of BCL-X expression
|
|
US6214986B1
(en)
*
|
1998-10-07 |
2001-04-10 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of bcl-x expression
|
|
US5962673A
(en)
*
|
1998-11-20 |
1999-10-05 |
Isis Pharmaceuticals Inc. |
Antisense modulation of inhibitor-kappa B kinase-alpha expression
|
|
US5959097A
(en)
*
|
1998-11-20 |
1999-09-28 |
Isis Pharmaceuticals, Inc. |
Antisense modulation of MEK2 expression
|
|
US5977341A
(en)
*
|
1998-11-20 |
1999-11-02 |
Isis Pharmaceuticals Inc. |
Antisense modulation of inhibitor-kappa B kinase-beta expression
|
|
US5981732A
(en)
*
|
1998-12-04 |
1999-11-09 |
Isis Pharmaceuticals Inc. |
Antisense modulation of G-alpha-13 expression
|
|
WO2000062736A2
(en)
*
|
1999-04-06 |
2000-10-26 |
East Carolina University |
Low adenosine anti-sense oligonucleotide, compositions, kit and method for treatment of airway disorders associated with bronchoconstriction, lung inflammation, allergy(ies) and surfactant depletion
|
|
US20040171566A1
(en)
*
|
1999-04-06 |
2004-09-02 |
Monia Brett P. |
Antisense modulation of p38 mitogen activated protein kinase expression
|
|
US6140124A
(en)
*
|
1999-04-06 |
2000-10-31 |
Isis Pharmaceuticals Inc. |
Antisense modulation of P38 mitogen activated protein kinase expression
|
|
US8143386B2
(en)
*
|
1999-04-07 |
2012-03-27 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis antigens and their uses
|
|
US6013788A
(en)
*
|
1999-04-09 |
2000-01-11 |
Isis Pharmaceuticals Inc. |
Antisense modulation of Smad3 expression
|
|
US6046321A
(en)
*
|
1999-04-09 |
2000-04-04 |
Isis Pharmaceuticals Inc. |
Antisense modulation of G-alpha-i1 expression
|
|
DE19935756A1
(de)
*
|
1999-07-27 |
2001-02-08 |
Mologen Forschungs Entwicklung |
Kovalent geschlossenes Nukleinsäuremolekül zur Immunstimulation
|
|
EP1496121A3
(en)
*
|
1999-08-13 |
2005-02-09 |
Hybridon, Inc. |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
|
|
EP2314693A3
(en)
*
|
1999-08-13 |
2012-11-28 |
Idera Pharmaceuticals, Inc. |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
|
|
AU779978B2
(en)
*
|
1999-10-07 |
2005-02-24 |
Corixa Corporation |
Fusion proteins of mycobacterium tuberculosis
|
|
CA2291367A1
(en)
*
|
1999-12-06 |
2001-06-06 |
Isabelle Henry |
Genetic constructions having a reduced or an increased number of epigenetic control regions and methods of use thereof
|
|
EP1322655B1
(en)
|
2000-01-14 |
2007-11-14 |
The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services |
Oligodeoxynucleotide and its use to induce an immune response
|
|
CN1254541C
(zh)
|
2000-02-23 |
2006-05-03 |
史密丝克莱恩比彻姆生物有限公司 |
新化合物
|
|
AU2001241738A1
(en)
*
|
2000-02-25 |
2001-09-03 |
Corixa Corporation |
Compounds and methods for diagnosis and immunotherapy of tuberculosis
|
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
|
US20040006036A1
(en)
*
|
2000-04-12 |
2004-01-08 |
Gmr, A Delaware Corporation |
Silencing transcription by methylation
|
|
WO2001090129A2
(en)
|
2000-05-19 |
2001-11-29 |
Corixa Corporation |
Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds
|
|
DE60139963D1
(de)
*
|
2000-06-20 |
2009-10-29 |
Corixa Corp |
Fusionsproteine aus mycobakterium tuberculosis
|
|
EP1319069B1
(en)
|
2000-06-28 |
2008-05-21 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of lung cancer
|
|
ATE384072T1
(de)
*
|
2000-09-26 |
2008-02-15 |
Idera Pharmaceuticals Inc |
Modulation der immunostimulatorischen aktivität von immunostimulierenden oligonukleotidanaloga durch positionelle chemische veränderungen
|
|
ES2307568T3
(es)
*
|
2000-12-08 |
2008-12-01 |
Coley Pharmaceutical Gmbh |
Acidos nucleicos de tipo cpg y metodos de uso de los mismos.
|
|
GB0105360D0
(en)
*
|
2001-03-03 |
2001-04-18 |
Glaxo Group Ltd |
Chimaeric immunogens
|
|
US7105495B2
(en)
*
|
2001-04-30 |
2006-09-12 |
Idera Pharmaceuticals, Inc. |
Modulation of oligonucleotide CpG-mediated immune stimulation by positional modification of nucleosides
|
|
CA2446788A1
(en)
|
2001-05-09 |
2002-11-14 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of prostate cancer
|
|
US7785610B2
(en)
*
|
2001-06-21 |
2010-08-31 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same—III
|
|
EP1404873B1
(en)
*
|
2001-06-21 |
2013-05-22 |
Dynavax Technologies Corporation |
Chimeric immunomodulatory compounds and methods of using the same
|
|
WO2003020884A2
(en)
|
2001-08-14 |
2003-03-13 |
The Government Of The United States Of America As Represented By The Secretary Of Health And Human Services |
Method for rapid generation of mature dendritic cells
|
|
ES2388170T3
(es)
|
2001-08-24 |
2012-10-09 |
Uvic Industry Partnerships Inc. |
Proaerolisina que contiene secuencias de activación de proteasa y métodos de uso para el tratamiento del cáncer de próstata
|
|
MXPA04002631A
(es)
*
|
2001-09-20 |
2004-07-08 |
Glaxo Group Ltd |
Vacunas de adn optimizadas por codon gag-vih.
|
|
AU2002353783A1
(en)
|
2001-09-24 |
2003-04-07 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of |
SUPPRESSORS OF CpG OLIGONUCLEOTIDES AND METHODS OF USE
|
|
US7276489B2
(en)
*
|
2002-10-24 |
2007-10-02 |
Idera Pharmaceuticals, Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5′ ends
|
|
WO2003035836A2
(en)
*
|
2001-10-24 |
2003-05-01 |
Hybridon Inc. |
Modulation of immunostimulatory properties of oligonucleotide-based compounds by optimal presentation of 5' ends
|
|
EP1456380B1
(en)
*
|
2001-11-02 |
2012-04-18 |
Giuliani International Limited |
Smad7 inhibitors for the treatment of cns diseases
|
|
EP1581119B1
(en)
|
2001-12-17 |
2013-01-30 |
Corixa Corporation |
Compositions and methods for the therapy and diagnosis of inflammatory bowel disease
|
|
AU2002366710A1
(en)
|
2001-12-20 |
2003-07-09 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of |
USE OF CpG OLIGODEOXYNUCLEOTIDES TO INDUCE ANGIOGENESIS
|
|
AU2003203079B8
(en)
*
|
2002-02-04 |
2009-01-15 |
Oncothyreon Inc. |
Immunostimulatory, covalently lipidated oligonucleotides
|
|
US7026465B2
(en)
*
|
2002-02-15 |
2006-04-11 |
Corixa Corporation |
Fusion proteins of Mycobacterium tuberculosis
|
|
AU2003263963A1
(en)
|
2002-08-01 |
2004-02-23 |
The Government Of The United States Of America As Represented By The Secretary Of The Department Of |
Method of treating inflammatory arthropathies with suppressors of cpg oligonucleotides
|
|
AR040996A1
(es)
|
2002-08-19 |
2005-04-27 |
Coley Pharm Group Inc |
Acidos nucleicos inmunoestimuladores
|
|
US8043622B2
(en)
|
2002-10-08 |
2011-10-25 |
The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services |
Method of treating inflammatory lung disease with suppressors of CpG oligonucleotides
|
|
DK1589934T3
(en)
|
2003-01-06 |
2015-12-21 |
Corixa Corp |
Certain AMINOAL COOLER GLUCOSAMINIDE PHOSPHATE COMPOUNDS AND APPLICATION
|
|
US7960522B2
(en)
|
2003-01-06 |
2011-06-14 |
Corixa Corporation |
Certain aminoalkyl glucosaminide phosphate compounds and their use
|
|
US7354907B2
(en)
*
|
2003-02-07 |
2008-04-08 |
Idera Pharmaceuticals, Inc. |
Short immunomodulatory oligonucleotides
|
|
EP1608403A2
(en)
*
|
2003-04-02 |
2005-12-28 |
Coley Pharmaceutical Group, Ltd. |
Immunostimulatory nucleic acid oil-in-water formulations for topical application
|
|
ITRM20030149A1
(it)
|
2003-04-02 |
2004-10-03 |
Giuliani Spa |
Oligonucleotidi (odn) antisenso per smad7 e loro usi in campo medico
|
|
AU2004275876B2
(en)
|
2003-09-25 |
2011-03-31 |
Coley Pharmaceutical Gmbh |
Nucleic acid-lipophilic conjugates
|
|
CN101454451A
(zh)
*
|
2003-10-30 |
2009-06-10 |
科勒制药有限公司 |
具有增强免疫刺激能力的c类寡核苷酸类似物
|
|
CA2565714C
(en)
|
2004-05-06 |
2014-12-23 |
The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services |
Methods and compositions for the treatment of uveitis
|
|
EP2497831B1
(en)
|
2004-05-25 |
2014-07-16 |
Oregon Health and Science University |
TB vaccination using HCMV-based vaccine vectors
|
|
GB0427131D0
(en)
*
|
2004-12-10 |
2005-01-12 |
Glaxosmithkline Biolog Sa |
Novel combination
|
|
WO2006065751A2
(en)
|
2004-12-13 |
2006-06-22 |
Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Cpg oligonucleotide prodrugs, compositions thereof and associated therapeutic methods
|
|
BRPI0609547A2
(pt)
|
2005-03-31 |
2011-10-18 |
Glaxosmithkline Biolog Sa |
composição, uso de uma composição, método para o tratamento ou prevenção de infecção por chlamydia, uso de uma ou mais proteìnas de chlamydia, de fragmentos imunogênicos das mesmas ou de polinucleotìdeos codificando os mesmos, método para o tratamento ou prevenção de infecção por chlamydia, e, método para a determinação prévia de infecção por chlamydia em um indivìduo
|
|
SI2457926T1
(sl)
|
2005-04-29 |
2015-01-30 |
Glaxosmithkline Biologicals S.A. |
Nov postopek za preprečevanje ali zdravljenje infekcije z M. tuberculosis
|
|
US8916161B2
(en)
|
2005-06-14 |
2014-12-23 |
Sophiris Bio Inc. |
Method of treating or preventing benign prostatic hyperplasia using modified pore-forming proteins
|
|
CN101517082B
(zh)
|
2006-09-27 |
2014-01-22 |
科勒制药有限责任公司 |
具有增强的免疫刺激活性的含疏水性T类似物的CpG寡聚核苷酸类似物
|
|
BRPI0809926B8
(pt)
*
|
2007-04-04 |
2021-05-25 |
Infectious Disease Res Inst |
composição que compreende antígenos de mycobacterium tuberculosis, polipeptídeo de fusão isolado, polinucleotídeo isolado que codifica o dito polipeptídeo e uso da dita composição para estimular uma resposta imune protetora
|
|
PE20090146A1
(es)
|
2007-04-20 |
2009-03-23 |
Glaxosmithkline Biolog Sa |
Composicion inmunogenica contra el virus influenza
|
|
WO2009006479A2
(en)
|
2007-07-02 |
2009-01-08 |
Etubics Corporation |
Methods and compositions for producing an adenovirus vector for use with multiple vaccinations
|
|
KR101811965B1
(ko)
|
2007-11-07 |
2017-12-22 |
셀덱스 쎄라퓨틱스, 인크. |
인간 수지상 및 상피 세포 205(ｄｅｃ-205)에 결합하는 항체
|
|
KR101617895B1
(ko)
|
2007-12-24 |
2016-05-03 |
글락소스미스클라인 바이오로지칼즈 에스.에이. |
재조합 ｒｓｖ 항원
|
|
EP2278979A4
(en)
|
2008-05-21 |
2012-09-26 |
Us Gov Health & Human Serv |
PROCESS FOR TREATING PNEUMOCONIOSIS WITH OLIGODEOXYNUCLEOTIDES
|
|
AU2009323996A1
(en)
|
2008-12-03 |
2011-07-07 |
Institut Pasteur |
Use of phenol-soluble modulins for vaccine development
|
|
MX2012000036A
(es)
|
2009-06-24 |
2012-02-28 |
Glaxosmithkline Biolog Sa |
Vacuna.
|
|
DK2445526T3
(en)
|
2009-06-24 |
2016-06-27 |
Glaxosmithkline Biologicals Sa |
Recombinant RSV antigens.
|
|
TW201116294A
(en)
|
2009-07-15 |
2011-05-16 |
Novartis Ag |
RSV F protein compositions and methods for making same
|
|
GB0919117D0
(en)
|
2009-10-30 |
2009-12-16 |
Glaxosmithkline Biolog Sa |
Process
|
|
WO2011101332A1
(en)
|
2010-02-16 |
2011-08-25 |
Proyecto De Biomedicina Cima, S.L. |
Compositions based on the fibronectin extracellular domain a for the treatment of melanoma
|
|
NZ602892A
(en)
|
2010-04-13 |
2014-08-29 |
Celldex Therapeutics Inc |
Antibodies that bind human cd27 and uses thereof
|
|
WO2012057904A1
(en)
|
2010-10-27 |
2012-05-03 |
Infectious Disease Research Institute |
Mycobacterium tuberculosis antigens and combinations thereof having high seroreactivity
|
|
EP2637687B1
(en)
|
2010-11-08 |
2021-01-06 |
Infectious Disease Research Institute |
Vaccines comprising non-specific nucleoside hydrolase and sterol 24-c-methyltransferase (smt) polypeptides for the treatment and diagnosis of leishmaniasis
|
|
EP2505640A1
(en)
|
2011-03-29 |
2012-10-03 |
Neo Virnatech, S.L. |
Vaccine compositions for birnavirus-borne diseases
|
|
GB201106357D0
(en)
|
2011-04-14 |
2011-06-01 |
Pessi Antonello |
Composition and uses thereof
|
|
CN103842374A
(zh)
|
2011-05-13 |
2014-06-04 |
诺华股份有限公司 |
融合前的rsv f抗原
|
|
CN103608030A
(zh)
|
2011-06-21 |
2014-02-26 |
昂科发克特公司 |
用于治疗和诊断癌症的组合物和方法
|
|
EP2666785A1
(en)
|
2012-05-23 |
2013-11-27 |
Affiris AG |
Complement component C5a-based vaccine
|
|
MX385774B
(es)
|
2012-08-03 |
2025-03-18 |
Infectious Disease Res Inst |
Composiciones para usarse en el tratamiento de una infección activa por mycobacterium tuberculosis.
|
|
SG11201500573RA
(en)
|
2012-08-06 |
2015-02-27 |
Glaxosmithkline Biolog Sa |
Method for eliciting in infants an immune response against rsv and b. pertussis
|
|
US20140037680A1
(en)
|
2012-08-06 |
2014-02-06 |
Glaxosmithkline Biologicals, S.A. |
Novel method
|
|
US9605276B2
(en)
|
2012-08-24 |
2017-03-28 |
Etubics Corporation |
Replication defective adenovirus vector in vaccination
|
|
EP2703483A1
(en)
|
2012-08-29 |
2014-03-05 |
Affiris AG |
PCSK9 peptide vaccine
|
|
PT2970398T
(pt)
|
2013-03-13 |
2024-06-07 |
The Us Secretary Department Ofhealth And Human Servic |
Proteínas f de pré-fusão do vsr e sua utilização
|
|
AR095425A1
(es)
|
2013-03-15 |
2015-10-14 |
Glaxosmithkline Biologicals Sa |
Vacuna, uso y procedimiento para prevenir una infección por picornavirus
|
|
WO2014160987A2
(en)
|
2013-03-28 |
2014-10-02 |
Infectious Disease Research Institute |
Vaccines comprising leishmania polypeptides for the treatment and diagnosis of leishmaniasis
|
|
AU2014304545A1
(en)
|
2013-08-05 |
2016-02-25 |
Glaxosmithkline Biologicals S.A. |
Combination immunogenic compositions
|
|
EP2952893A1
(en)
|
2014-06-04 |
2015-12-09 |
Institut d'Investigació Biomèdica de Bellvitge (IDIBELL) |
Method for detecting antibody-secreting B cells specific for HLA
|
|
US11571472B2
(en)
|
2014-06-13 |
2023-02-07 |
Glaxosmithkline Biologicals Sa |
Immunogenic combinations
|
|
AR102547A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso
|
|
AR102548A1
(es)
|
2014-11-07 |
2017-03-08 |
Takeda Vaccines Inc |
Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso
|
|
CN107278206B
(zh)
|
2014-12-19 |
2021-04-02 |
雷根尼桑斯公司 |
结合人c6的抗体及其用途
|
|
AU2016205215B2
(en)
|
2015-01-09 |
2021-03-11 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
|
WO2016140702A1
(en)
|
2015-03-03 |
2016-09-09 |
The United States Of America, As Represented By The Secretary, Department Of Health & Human Serivces |
Display platform from bacterial spore coat proteins
|
|
EP3268037B1
(en)
|
2015-03-09 |
2022-08-31 |
Celldex Therapeutics, Inc. |
Cd27 agonists
|
|
US11149087B2
(en)
|
2015-04-20 |
2021-10-19 |
Etubics Corporation |
Methods and compositions for combination immunotherapy
|
|
WO2016191553A1
(en)
|
2015-05-26 |
2016-12-01 |
Ohio State Innovation Foundation |
Nanoparticle based vaccine strategy against swine influenza virus
|
|
LU92821B1
(en)
|
2015-09-09 |
2017-03-20 |
Mologen Ag |
Combination comprising immunostimulatory oligonucleotides
|
|
GB2542425A
(en)
|
2015-09-21 |
2017-03-22 |
Mologen Ag |
Means for the treatment of HIV
|
|
JP7038064B2
(ja)
|
2016-04-18 |
2022-03-17 |
セルデックス セラピューティクス インコーポレイテッド |
ヒトｃｄ４０に結合するアゴニスト抗体およびその使用
|
|
MX2018014270A
(es)
|
2016-05-21 |
2019-02-14 |
Infectious Disease Res Inst |
Composiciones y metodos para tratar la tuberculosis secundaria e infecciones po micobacteria no tuberculosa.
|
|
JP2019517577A
(ja)
|
2016-05-27 |
2019-06-24 |
エトゥビクス コーポレーション |
ネオエピトープワクチン組成物及びその使用方法
|
|
CA3036218A1
(en)
|
2016-09-16 |
2018-03-22 |
Infectious Disease Research Institute |
Vaccines comprising mycobacterium leprae polypeptides for the prevention, treatment, and diagnosis of leprosy
|
|
WO2018109220A2
(en)
|
2016-12-16 |
2018-06-21 |
Institute For Research In Biomedicine |
Novel recombinant prefusion rsv f proteins and uses thereof
|
|
WO2018162450A1
(en)
|
2017-03-06 |
2018-09-13 |
Fundación Para La Investigación Médica Aplicada |
New inmunostimulatory compositions comprising an entity of cold inducible rna-binding protein with an antigen for the activation of dendritic cells
|
|
CN110945022B
(zh)
|
2017-04-19 |
2024-04-05 |
生物医学研究所 |
作为疫苗及新疟疾疫苗和抗体结合靶标的疟原虫子孢子npdp肽
|
|
KR102673794B1
(ko)
|
2017-06-15 |
2024-06-11 |
액세스 투 어드밴스드 헬스 인스티튜트 |
나노구조 지질 담체 및 안정적인 에멀션 그리고 이들의 용도
|
|
WO2019035963A1
(en)
|
2017-08-16 |
2019-02-21 |
Ohio State Innovation Foundation |
NANOPARTICLE COMPOSITIONS FOR VACCINES AGAINST SALMONELLA
|
|
CA3081586A1
(en)
|
2017-11-03 |
2019-05-09 |
Takeda Vaccines, Inc. |
Zika vaccines and immunogenic compositions, and methods of using the same
|
|
CN111836639A
(zh)
|
2018-01-26 |
2020-10-27 |
河谷细胞有限公司 |
用于联合癌症疫苗和免疫辅助疗法的组合物和方法
|
|
WO2019183570A1
(en)
|
2018-03-22 |
2019-09-26 |
Board Of Regents, The University Of Texas System |
Soluble interleukin-7 receptor (sil7r) molulating therapy to treat autoimmune diseases and cancer
|
|
WO2019204462A2
(en)
|
2018-04-17 |
2019-10-24 |
Celldex Therapeutics, Inc. |
Anti-cd27 and anti-pd-l1 antibodies and bispecific constructs
|
|
CA3174411A1
(en)
|
2020-09-04 |
2022-03-10 |
Ryan M. Kramer |
Co-lyophilized rna and nanostructured lipid carrier
|
|
EP4320159A1
(en)
|
2021-04-09 |
2024-02-14 |
Celldex Therapeutics, Inc. |
Antibodies against ilt4, bispecific anti-ilt4/pd-l1 antibody and uses thereof
|
|
WO2023077521A1
(en)
|
2021-11-08 |
2023-05-11 |
Celldex Therapeutics, Inc |
Anti-ilt4 and anti-pd-1 bispecific constructs
|
|
US20250082745A1
(en)
|
2021-12-13 |
2025-03-13 |
The U.S.A., As Represented By The Secretary, Department Of Health And Human Services |
Bacteriophage lambda-vaccine system
|
|
EP4583841A1
(en)
|
2022-09-09 |
2025-07-16 |
Access to Advanced Health Institute |
Immunogenic vaccine composition incorporating a saponin
|
|
CN121219315A
(zh)
|
2023-03-03 |
2025-12-26 |
塞德斯医疗公司 |
抗干细胞因子(scf)和抗胸腺基质淋巴细胞生成素(tslp)抗体及双特异性构建体
|